Week of March 7th 2022 | Vol. 11, Issue 10
Events Hosted or Attended by Bourne Partners
March 16-18, 2022 - Aventura, FL
March 21-24, 2022 - New York City, NY
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
April 23-26, 2022 - Palm Beach, FL
June 13-16, 2022 - San Diego, CA
April 23-26, 2022 - Palm Beach, FL
October 2022 - Charlotte, NC
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
Insight Into Healthcare Related Industries
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
A Sampling of Industry Headlines From Last Week
Sanofi seems to be in a betting mood and has been picking up card after card in licensing deals to bulk up its early-stage pipeline.
When Christopher Austin, M.D., and Doug Cole, M.D., were co-residents at Massachusetts General Hospital in the late '80s, they realized the diagnoses and treatments for common diseases were "both problematic."
This morning, the Biden administration released a 96-page strategy outlining tactics to mitigate COVID-19 cases and prepare for future surges with limited shutdowns.
The contingent of biotech and pharma companies condemning Russia’s invasion of Ukraine—and pledging to help keep the beleaguered nation’s healthcare system afloat—is growing.

Discover more about the connection between real-world data capture and early access programs, and the role this plays in the approval of life-improving medicines.